GlassScriptPhysician profile
Casey A Jennings
NPI 1033300488
$8,031.49
in general payments reported to CMS, 2019-2025
50 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $1,250 · 2021: $1,181 · 2022: $1,210 · 2023: $1,213 · 2024: $770 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,848.74 |
| Education | $192.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,274.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $736.73 | 2019-2025 | |
| Amgen INC. | $609.76 | 2019-2025 | Repatha, Otezla, Evenity |
| Teva Pharmaceuticals USA, INC. | $604.81 | 2020-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Pfizer INC. | $549.17 | 2019-2025 | |
| Lilly USA, LLC | $546.54 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $342.13 | 2019-2024 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $311.61 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.75 | 2019-2023 | Jardiance |
| Mylan Specialty L.P. | $230.85 | 2019-2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $210.15 | 2019-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $205.92 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $201.48 | 2022 | |
| Sanofi-Aventis U.S. LLC | $174.43 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $154.41 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.